1. Home
  2. DUO vs BRTX Comparison

DUO vs BRTX Comparison

Compare DUO & BRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

DUO

Fangdd Network Group Ltd.

HOLD

Current Price

$1.12

Market Cap

7.5M

Sector

Finance

ML Signal

HOLD

Logo BioRestorative Therapies Inc. (NV)

BRTX

BioRestorative Therapies Inc. (NV)

HOLD

Current Price

$0.46

Market Cap

6.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DUO
BRTX
Founded
2011
1997
Country
China
United States
Employees
N/A
N/A
Industry
Real Estate
Managed Health Care
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.5M
6.3M
IPO Year
2018
2015

Fundamental Metrics

Financial Performance
Metric
DUO
BRTX
Price
$1.12
$0.46
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
55.7K
21.8M
Earning Date
05-12-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$81,000.00
Revenue This Year
N/A
$298.39
Revenue Next Year
N/A
$64.62
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.19
$0.16
52 Week High
$5.34
$2.04

Technical Indicators

Market Signals
Indicator
DUO
BRTX
Relative Strength Index (RSI) 37.13 80.85
Support Level $1.02 $0.20
Resistance Level $1.25 $1.20
Average True Range (ATR) 0.10 0.06
MACD -0.04 0.03
Stochastic Oscillator 25.39 58.88

Price Performance

Historical Comparison
DUO
BRTX

About DUO Fangdd Network Group Ltd.

Fangdd Network Group Ltd is an investment holding company. It is engaged in the provision of real estate information services through its online platform which also offers integrated marketing services for individual customers, real estate developers, and agents in China. Its SaaS-based solutions help real estate agents to connect with essential business resources, including customers, property listings, capital, and transaction data. The company generates the majority of its revenue from Base commission from transactions in China.

About BRTX BioRestorative Therapies Inc. (NV)

BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.

Share on Social Networks: